Jonathan Rabinowitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5672050/publications.pdf

Version: 2024-02-01

184 papers

9,131 citations

51 h-index 90 g-index

191 all docs

191 docs citations

191 times ranked

8429 citing authors

#	Article	IF	CITATIONS
1	Outlier-response pattern checks to improve measurement with the Montgomery-Asberg depression rating scale (MADRS). Journal of Affective Disorders, 2022, 299, 444-448.	4.1	3
2	Consistency checks to improve measurement with the Hamilton Rating Scale for Depression (HAM-D). Journal of Affective Disorders, 2022, 302, 273-279.	4.1	7
3	Early predictors of mental health in midâ€adulthood. Microbial Biotechnology, 2021, 15, 158-166.	1.7	4
4	Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP). Schizophrenia Research, 2021, 228, 529-533.	2.0	6
5	Outlier-response pattern checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Psychiatry Research, 2021, 303, 114114.	3.3	3
6	Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophrenia Research, 2019, 211, 103-104.	2.0	7
7	Low-dose ladostigil for mild cognitive impairment. Neurology, 2019, 93, e1474-e1484.	1.1	40
8	Modelâ€Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response. Clinical Pharmacology and Therapeutics, 2019, 106, 1253-1260.	4.7	5
9	Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS). Journal of Affective Disorders, 2019, 256, 143-147.	4.1	12
10	Determinants of antidepressant response: Implications for practice and future clinical trials. Journal of Affective Disorders, 2018, 239, 79-84.	4.1	7
11	Psychiatric symptoms and related dysfunction in a general population sample. Schizophrenia Research: Cognition, 2018, 14, 1-6.	1.3	5
12	Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 2017, 190, 74-76.	2.0	11
13	Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. American Journal of Psychiatry, 2017, 174, 1195-1202.	7.2	68
14	Association of childhood and teen school performance and obesity in young adulthood in the US National Longitudinal Survey of Youth. Preventive Medicine, 2016, 89, 57-63.	3.4	4
15	Initial depression severity and response to antidepressants <i>v.</i> placebo: patient-level data analysis from 34 randomised controlled trials. British Journal of Psychiatry, 2016, 209, 427-428.	2.8	52
16	Study of resilience and environmental adversity in midlife health (STREAM). Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1915-1922.	3.1	3
17	Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. European Neuropsychopharmacology, 2015, 25, 1578-1585.	0.7	5
18	Usefulness of interim analyses in portending study results in antipsychotic and antidepressant trials. European Neuropsychopharmacology, 2015, 25, 1999-2007.	0.7	0

#	Article	IF	Citations
19	How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. European Neuropsychopharmacology, 2014, 24, 1279-1288.	0.7	13
20	Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset. European Neuropsychopharmacology, 2014, 24, 1615-1621.	0.7	5
21	Combining efficacy and completion rates with no data imputation: A composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials. European Neuropsychopharmacology, 2014, 24, 357-368.	0.7	2
22	Determinants of Antipsychotic Response in Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, e308-e316.	2.2	56
23	Clinical trials for negative symptoms — Emerging directions and unresolved issues. Schizophrenia Research, 2013, 150, 327.	2.0	8
24	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
25	Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis. Schizophrenia Research, 2013, 150, 339-342.	2.0	86
26	Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophrenia Research, 2013, 150, 334-338.	2.0	59
27	Schoolâ€based obesity prevention programs: A metaâ€analysis of randomized controlled trials. Obesity, 2013, 21, 2422-2428.	3.0	178
28	Comparing Symptom Response Among Antipsychotic Medications in CATIE. Journal of Clinical Psychopharmacology, 2013, 33, 123-126.	1.4	2
29	Hopelessness as a Predictor of Attempted Suicide among First Admission Patients with Psychosis: A 10â€year Cohort Study. Suicide and Life-Threatening Behavior, 2012, 42, 1-10.	1.9	159
30	Poster #189 COMPARING SYMPTOM RESPONSE AMONG ANTIPSYCHOTIC MEDICATIONS IN CATIE. Schizophrenia Research, 2012, 136, S253-S254.	2.0	0
31	Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research, 2012, 137, 141-146.	2.0	42
32	Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 2012, 137, 147-150.	2.0	305
33	Real-world premorbid functioning in schizophrenia and affective disorders during the early teenage years: A population-based study of school grades and teacher ratings. Schizophrenia Research, 2012, 136, 13-18.	2.0	15
34	Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15Âyears. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 303-311.	3.1	18
35	BL-1020, a New γ-Aminobutyric Acid–Enhanced Antipsychotic. Journal of Clinical Psychiatry, 2012, 73, e1168-e1174.	2.2	34
36	Hopelessness as a Predictor of Attempted Suicide among First Admission Patients with Psychosis: A 10-year Cohort Study. Suicide and Life-Threatening Behavior, 2012, , no-no.	1.9	2

#	Article	IF	Citations
37	Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Schizophrenia Research, 2011, 133, 42-46.	2.0	35
38	Recommendations to improve the Positive and Negative Syndrome Scale (PANSS) based on item response theory. Psychiatry Research, 2011, 188, 446-452.	3.3	40
39	Premorbid Functioning and Treatment Response in Recent-Onset Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 75-81.	1.4	18
40	Disparities in obesity temporal trends of Israeli adolescents by ethnic origin. Pediatric Obesity, 2011, 6, e154-e161.	3.2	10
41	The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled study. European Journal of Applied Physiology, 2011, 111, 2261-2269.	2.5	72
42	Concordance Between Measures of Functioning, Symptoms, and Change. Journal of Clinical Psychopharmacology, 2010, 30, 478-480.	1.4	19
43	Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis. Journal of Clinical Psychopharmacology, 2010, 30, 446-449.	1.4	35
44	Risperidone Long-Acting Injectable in Recent-Onset Schizophrenia Examined With Clinician and Patient Self-Report Measures. Journal of Clinical Psychopharmacology, 2010, 30, 200-202.	1.4	13
45	Antecedents and Patterns of Suicide Behavior in First-Admission Psychosis. Schizophrenia Bulletin, 2010, 36, 880-889.	4.3	52
46	Body Fat Measurements in Elite Adolescent Volleyball Players: Correlation between Skinfold Thickness, Bioelectrical Impedance Analysis, Air-displacement Plethysmography, and Body Mass Index Percentiles. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 395-400.	0.9	13
47	Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis. Schizophrenia Bulletin, 2010, 36, 624-632.	4.3	56
48	Is poor premorbid functioning a risk factor for suicide attempts in first-admission psychosis?. Schizophrenia Research, 2010, 116, 210-216.	2.0	15
49	PREMORBID FUNCTIONING AND TREATMENT RESPONSE AMONG PATIENTS WITH RECENT ONSET SCHIZOPHRENIA: PROSPECTIVE STUDY WITH RISPERIDONE LONG-ACTING INJECTABLE-PROPEL STUDY. Schizophrenia Research, 2010, 117, 317.	2.0	0
50	CONCORDANCE BETWEEN MEASURES OF FUNCTIONING, SYMPTOMATOLOGY AND CHANGE: GAF, CGI-S, CGI-C AND PANSS. Schizophrenia Research, 2010, 117, 400.	2.0	0
51	A POPULATION-BASED ELABORATION ON PREMORBID FUNCTIONING IN SCHIZOPHRENIA DURING THE EARLY TEENAGE YEARS: COMPARISON, INCIDENCE AND ONSET. Schizophrenia Research, 2010, 117, 431-432.	2.0	0
52	Correlates, change and â€~state or trait' properties of insight in schizophrenia. Schizophrenia Research, 2010, 122, 94-103.	2.0	76
53	Suicide attempts at the time of first admission and during early course schizophrenia: A population based study. Psychiatry Research, 2010, 177, 55-59.	3.3	22
54	Insight: Demographic Differences and Associations with One-Year Outcome in Schizophrenia and Schizoaffective Disorder. Clinical Schizophrenia and Related Psychoses, 2010, 4, 169-175.	1.4	30

#	Article	IF	CITATIONS
55	Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. Schizophrenia Bulletin, 2009, 35, 775-788.	4.3	58
56	A population-based examination of the role of years of education, age of onset, and sex on the course of schizophrenia. Psychiatry Research, 2009, 168, 11-17.	3.3	15
57	Population-Based Trends in Male Adolescent Obesity in Israel 1967–2003. Journal of Adolescent Health, 2009, 44, 195-198.	2.5	31
58	Pathways to functional outcomes in schizophrenia: The role of premorbid functioning, negative symptoms and intelligence. Schizophrenia Research, 2009, 110, 40-46.	2.0	42
59	Neuropsychological Function and Dysfunction in Schizophrenia and Psychotic Affective Disorders. Schizophrenia Bulletin, 2009, 35, 1022-1029.	4.3	427
60	The Effect of a Volleyball Practice on Anabolic Hormones and Inflammatory Markers in Elite Male and Female Adolescent Players. Journal of Strength and Conditioning Research, 2009, 23, 1553-1559.	2.1	26
61	Dysthymia in male adolescents is associated with increased risk of later hospitalization for psychotic disorders: a historical-prospective cohort study. Microbial Biotechnology, 2008, 2, 67-72.	1.7	6
62	Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophrenia Research, 2008, 98, 318-322.	2.0	103
63	Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Schizophrenia Research, 2008, 100, 359-360.	2.0	14
64	Subtle Cognitive Dysfunction in Nonaffected Siblings of Individuals Affected by Nonpsychotic Disorders. Biological Psychiatry, 2008, 63, 602-608.	1.3	18
65	Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies. Clinical Therapeutics, 2008, 30, 2378-2386.	2.5	71
66	A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications. Schizophrenia Bulletin, 2008, 34, 1145-1150.	4.3	15
67	Validity of the Premorbid Adjustment Scale. Schizophrenia Bulletin, 2008, 34, 981-983.	4.3	53
68	Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International Clinical Psychopharmacology, 2008, 23, 325-331.	1.7	84
69	Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. Journal of Clinical Psychopharmacology, 2008, 28, 210-213.	1.4	87
70	The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data. Schizophrenia Bulletin, 2007, 34, 286-291.	4.3	30
71	Revisiting the 5 Dimensions of the Positive and Negative Syndrome Scale. Journal of Clinical Psychopharmacology, 2007, 27, 431-436.	1.4	58
72	Impaired Reading Comprehension and Mathematical Abilities in Male Adolescents With Average or Above General Intellectual Abilities Are Associated With Comorbid and Future Psychopathology. Journal of Nervous and Mental Disease, 2007, 195, 883-890.	1.0	18

#	Article	IF	Citations
73	Social and cognitive functioning, urbanicity and risk for schizophrenia. British Journal of Psychiatry, 2007, 191, 320-324.	2.8	62
74	Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone. International Psychogeriatrics, 2007, 19, 227.	1.0	27
75	Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophrenia Research, 2007, 89, 129-139.	2.0	180
76	The Premorbid Adjustment Scale Structured Interview (PAS-SI): Preliminary findings. Schizophrenia Research, 2007, 90, 255-257.	2.0	25
77	The course of schizophrenia: Progressive deterioration, amelioration or both?. Schizophrenia Research, 2007, 91, 254-258.	2.0	44
78	Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs. Schizophrenia Research, 2007, 94, 45-49.	2.0	14
79	Accuracy of self-reported premorbid functioning in schizophrenia. Schizophrenia Research, 2007, 97, 103-108.	2.0	28
80	Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: A population-based study. Schizophrenia Research, 2006, 85, 49-57.	2.0	47
81	A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophrenia Research, 2006, 88, 96-101.	2.0	144
82	Premorbid functioning and treatment response in recent-onset schizophrenia. British Journal of Psychiatry, 2006, 189, 31-35.	2.8	59
83	The Relationship of Premorbid Functioning to Illness Course in Schizophrenia and Psychotic Mood Disorders During Two Years Following First Hospitalization. Journal of Nervous and Mental Disease, 2006, 194, 791-795.	1.0	50
84	Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia. American Journal of Psychiatry, 2006, 163, 743-745.	7.2	130
85	To What Extent Do the PANSS and CGI-S Overlap?. Journal of Clinical Psychopharmacology, 2006, 26, 303-307.	1.4	38
86	Advancing Paternal Age and Autism. Archives of General Psychiatry, 2006, 63, 1026.	12.3	557
87	Socioeconomic Status at Birth Is Associated With Risk of Schizophrenia: Population-Based Multilevel Study. Schizophrenia Bulletin, 2006, 33, 1373-1378.	4.3	148
88	Premorbid Intellectual Functioning and Risk of Schizophrenia and Spectrum Disorders. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 193-207.	1.3	86
89	Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia. American Journal of Psychiatry, 2006, 163, 743.	7.2	86
90	Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. British Journal of Psychiatry, 2005, 187, 131-136.	2.8	89

#	Article	IF	Citations
91	Elaboration on Premorbid Intellectual Performance in Schizophrenia. Archives of General Psychiatry, 2005, 62, 1297.	12.3	146
92	Paternal age and intelligence: implications for age-related genomic changes in male germ cells. Psychiatric Genetics, 2005, 15, 117-125.	1.1	147
93	Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. Journal of Psychopharmacology, 2005, 19, 277-285.	4.0	55
94	Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial. American Journal of Psychiatry, 2005, 162, 947-953.	7.2	331
95	Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial. American Journal of Psychiatry, 2005, 162, 1888-1895.	7.2	148
96	Factor Analysis of the Cohen-Mansfield Agitation Inventory in Three Large Samples of Nursing Home Patients With Dementia and Behavioral Disturbance. American Journal of Geriatric Psychiatry, 2005, 13, 991-998.	1.2	54
97	Association between functioning in adolescence prior to first admission for schizophrenia and affective disorders and patterns of hospitalizations thereafter. Schizophrenia Research, 2005, 73, 185-191.	2.0	17
98	Primary Care Physicians' Detection of Psychological Distress Among Elderly Patients. American Journal of Geriatric Psychiatry, 2005, 13, 773-780.	1.2	7
99	Factor Analysis of the Cohen-Mansfield Agitation Inventory in Three Large Samples of Nursing Home Patients With Dementia and Behavioral Disturbance. American Journal of Geriatric Psychiatry, 2005, 13, 991-998.	1.2	45
100	Primary Care Physicians' Detection of Psychological Distress Among Elderly Patients. American Journal of Geriatric Psychiatry, 2005, 13, 773-780.	1.2	6
101	Cognitive performance of male adolescents is lower than controls across psychiatric disorders: a population-based study. Acta Psychiatrica Scandinavica, 2004, 110, 471-475.	4.5	43
102	Correlates of cognitive deficits in first episode schizophrenia. Schizophrenia Research, 2004, 68, 1-9.	2.0	171
103	The relationship of neuropsychological test performance with the PANSS in antipsychotic na $\tilde{\mathbb{A}}$ -ve, first-episode psychosis patients. Schizophrenia Research, 2004, 68, 11-19.	2.0	55
104	Correlates of insight in first episode psychosis. Schizophrenia Research, 2004, 70, 187-194.	2.0	167
105	Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study. American Journal of Psychiatry, 2004, 161, 1219-1223.	7.2	152
106	Behavioral and Psychological Symptoms in Patients With Dementia as a Target for Pharmacotherapy With Risperidone. Journal of Clinical Psychiatry, 2004, 65, 1329-1334.	2.2	28
107	The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophrenia Research, 2003, 61, 47-57.	2.0	329
108	Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?. Schizophrenia Research, 2003, 61, 149-155.	2.0	30

#	Article	IF	Citations
109	Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophrenia Research, 2003, 65, 87-94.	2.0	156
110	Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophrenia. Biological Psychiatry, 2003, 54, 655-660.	1.3	43
111	The relationship of neuropsychological test performance with the PANSS in antipsychotic naÃve, first-episode psychosis patients. Schizophrenia Research, 2003, 68, 11-11.	2.0	0
112	Perceived Need and Receipt of Outpatient Mental Health Services. Journal of Ambulatory Care Management, 2003, 26, 260-269.	1.1	5
113	PERCEIVED PATIENT THREAT AND NEUROLEPTIC DOSAGE. Journal of Nervous and Mental Disease, 2003, 191, 129-130.	1.0	1
114	PERCEIVED PATIENT THREAT AND NEUROLEPTIC DOSAGE. Journal of Nervous and Mental Disease, 2003, 191, 129-130.	1.0	2
115	Differences in Age of First Hospitalization for Schizophrenia Among Immigrants and Nonimmigrants in a National Case Registry. Schizophrenia Bulletin, 2002, 28, 491-499.	4.3	14
116	A Population-Based Cohort Study of Premorbid Intellectual, Language, and Behavioral Functioning in Patients With Schizophrenia, Schizoaffective Disorder, and Nonpsychotic Bipolar Disorder. American Journal of Psychiatry, 2002, 159, 2027-2035.	7.2	318
117	Relationship Between Premorbid Functioning and Symptom Severity as Assessed at First Episode of Psychosis. American Journal of Psychiatry, 2002, 159, 2021-2026.	7.2	86
118	Patients' and Staff Members' Attitudes About the Rights of Hospitalized Psychiatric Patients. Psychiatric Services, 2002, 53, 87-91.	2.0	22
119	Predictions Made by Psychiatrists and Psychiatric Nurses of Violence by Patients. Psychiatric Services, 2002, 53, 622-624.	2.0	27
120	Motivation to serve in the military influences vulnerability to future posttraumatic stress disorder. Psychiatry Research, 2002, 109, 45-49.	3.3	41
121	Outcomes of Naltrexone Maintenance Following Ultra Rapid Opiate Detoxification Versus Intensive Inpatient Detoxification. American Journal on Addictions, 2002, 11, 52-56.	1.4	15
122	Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophrenia Research, 2001, 50, 89-93.	2.0	19
123	Post-traumatic stress disorder in primary-care settings: prevalence and physicians' detection. Psychological Medicine, 2001, 31, 555-560.	4.5	97
124	Association Between Nonpsychotic Psychiatric Diagnoses in Adolescent Males and Subsequent Onset of Schizophrenia. Archives of General Psychiatry, 2001, 58, 959.	12.3	99
125	Rehospitalization Rates of Chronically Ill Schizophrenic Patients Discharged on a Regimen of Risperidone, Olanzapine, or Conventional Antipsychotics. American Journal of Psychiatry, 2001, 158, 266-269.	7.2	102
126	Changes in Insurance Coverage and Extent of Care During the Two Years After First Hospitalization for a Psychotic Disorder. Psychiatric Services, 2001, 52, 87-91.	2.0	17

#	Article	IF	Citations
127	Short Report: Comparison of Patient Satisfaction and Burden of Adverse Effects With Novel and Conventional Neuroleptics: A Naturalistic Study. Schizophrenia Bulletin, 2001, 27, 597-600.	4.3	20
128	Rapid Onset of Therapeutic Effect of Risperidone Versus Haloperidol in a Double-Blind Randomized Trial. Journal of Clinical Psychiatry, 2001, 62, 343-346.	2.2	17
129	Premorbid Functioning in a National Population of Male Twins Discordant for Psychoses. American Journal of Psychiatry, 2000, 157, 1514-1516.	7.2	42
130	Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital. British Journal of Psychiatry, 2000, 177, 26-32.	2.8	88
131	Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophrenia Research, 2000, 46, 91-96.	2.0	25
132	Gender differences in premorbid cognitive performance in a national cohort of schizophrenic patients. Schizophrenia Research, 2000, 45, 185-190.	2.0	44
133	Dr. Davidson and Colleagues Reply. American Journal of Psychiatry, 2000, 157, 1528-1528.	7.2	1
134	Correlates of a perceived need for mental health assistance and differences between those who do and do not seek help. Social Psychiatry and Psychiatric Epidemiology, 1999, 34, 141-146.	3.1	80
135	Accuracy and Confidence in Clinical Assessment of Psychiatric Inpatients Risk of Violence. International Journal of Law and Psychiatry, 1999, 22, 99-106.	0.9	29
136	A Naturalistic Study Comparing the Efficacy of a Memory Enhancement Course to a General Academic Course. International Psychogeriatrics, 1999, 11, 281-287.	1.0	4
137	Involuntary First Admission of Patients With Schizophrenia as a Predictor of Future Admissions. Psychiatric Services, 1999, 50, 1049-1052.	2.0	54
138	Risk factors for violence among longâ€stay psychiatric patients: national study. Acta Psychiatrica Scandinavica, 1999, 99, 341-347.	4.5	27
139	Implementation of Order of Compulsory Ambulatory Treatment in Jerusalem. International Journal of Law and Psychiatry, 1998, 21, 65-71.	0.9	8
140	Relationship Between Type of Insurance and Care During the Early Course of Psychosis. American Journal of Psychiatry, 1998, 155, 1392-1397.	7.2	31
141	Which Primary Care Physicians Treat Depression?. Psychiatric Services, 1998, 49, 100-102.	2.0	8
142	Alcohol & Drug Abuse: Predictors of Being Expelled From and Dropping Out of Alcohol Treatment. Psychiatric Services, 1998, 49, 187-189.	2.0	23
143	Outcomes of Ultrarapid Opiate Detoxification Combined With Naltrexone Maintenance and Counseling. Psychiatric Services, 1998, 49, 831-833.	2.0	14
144	Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine, 1998, 28, 1411-1419.	4.5	136

#	Article	IF	CITATIONS
145	Clinicians' predictions of length of psychotherapy. Psychiatric Services, 1997, 48, 97-99.	2.0	15
146	Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. American Journal of Psychiatry, 1997, 154, 475-482.	7.2	143
147	Revamping Mental Health Care in Israel. Social Work in Health Care, 1997, 25, 119-129.	1.6	10
148	Predictors of assaultive long-stay schizophrenic patients: National study. Schizophrenia Research, 1997, 24, 21.	2.0	0
149	Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug and Alcohol Dependence, 1997, 47, 77-86.	3.2	61
150	Physical illness among all discharged psychiatric inpatients in a national case register. Journal of Mental Health Administration, 1997, 24, 82-89.	1.1	8
151	Effect of clozapine on physical and verbal aggression. Schizophrenia Research, 1996, 22, 249-255.	2.0	58
152	Primary Health Care Physicians' Treatment of Psychosocial Problems: Implications for Social Work. Health and Social Work, 1996, 21, 89-95.	1.0	12
153	Patterns of Use Changes in Diagnosis during First Admission. Psychopathology, 1996, 29, 39-45.	1.5	2
154	Reform in mental health services in Israel: The changing role of government, HMOs, and hospitals. Administration and Policy in Mental Health and Mental Health Services Research, 1996, 23, 253-259.	2.1	12
155	Agreement between therapists and clients in evaluating therapy and its outcomes: Literature review. Administration and Policy in Mental Health and Mental Health Services Research, 1996, 23, 493-511.	2.1	23
156	Who comes to the psychiatric emergency room and how they are helped. Administration and Policy in Mental Health and Mental Health Services Research, 1996, 23, 425-437.	2.1	5
157	Reported comorbidity of mental disorders with substance abuse among psychiatric inpatients in israel. Journal of Mental Health Administration, 1996, 23, 471-478.	1.1	13
158	Review of family treatment studies in israel. Contemporary Family Therapy, 1996, 18, 161-193.	1.3	2
159	A method for understanding admission decision making in a psychiatric emergency room. Psychiatric Services, 1995, 46, 1055-1060.	2.0	22
160	Effects of psychosocial rehabilitation for hospitalized mentally ill homeless persons. Psychiatric Services, 1995, 46, 948-950.	2.0	0
161	Factors influencing disposition decisions for patients seen in a psychiatric emergency service. Psychiatric Services, 1995, 46, 712-718.	2.0	46
162	Predicting revolving-door patients in a 9-year national sample. Social Psychiatry and Psychiatric Epidemiology, 1995, 30, 65-72.	3.1	39

#	Article	IF	CITATIONS
163	Detecting psychological distress among patients attending secondary health care clinics. General Hospital Psychiatry, 1995, 17, 425-432.	2.4	12
164	Pain Complaints and Psychological Distress among Soldiers in Specialty Military Medical Clinics. Military Medicine, 1995, 160, 213-216.	0.8	4
165	Effectiveness of Clozapine in Hospitalised People with Chronic Neuroleptic-Resistant Schizophrenia. British Journal of Psychiatry, 1995, 167, 760-764.	2.8	20
166	Clinical Decision Making of Short-Versus Long-Term Treatment. Research on Social Work Practice, 1995, 5, 62-79.	1.9	5
167	The Talbieh Brief Distress Inventory: A brief instrument to measure psychological distress among immigrants. Comprehensive Psychiatry, 1995, 36, 448-453.	3.1	80
168	How individual clinicians make admission decisions in psychiatric emergency rooms. Journal of Psychiatric Research, 1994, 28, 475-482.	3.1	21
169	The role of mental health practitioners' testimony in the Israeli Supreme Court. International Journal of Law and Psychiatry, 1994, 17, 395-407.	0.9	4
170	Changes in diagnosis in a 9-year national longitudinal sample. Comprehensive Psychiatry, 1994, 35, 361-365.	3.1	56
171	Understanding who improves after psychiatric hospitalization. Acta Psychiatrica Scandinavica, 1994, 89, 152-158.	4.5	24
172	Benefits of a Structured Format for Paper and Computerized Psychiatric Case Records. Psychiatric Services, 1993, 44, 1095-1097.	2.0	2
173	Brief Treatment of Anorexia Nervosa in Military Personnel. Psychiatric Services, 1993, 44, 69-71.	2.0	1
174	Why and How to Establish a Computerized System for Psychiatric Case Records. Psychiatric Services, 1993, 44, 1091-1095.	2.0	6
175	The Effect of Demographic Dynamics on Jewish Communal Participation in the United States. SA Sociological Analysis, 1992, 53, 287.	0.2	1
176	Collective Decision-Making: the Analytic Hierarchy Process. Social Policy and Administration, 1992, 26, 87-97.	3.0	3
177	A System for Improving Psychiatric Record Keeping. Psychiatric Services, 1991, 42, 1163-1166.	2.0	0
178	Successful Replacement of Traditional Psychiatric Records With a Multi-User Computer System. Medical Care, 1991, 29, 1057-1060.	2.4	5
179	The paradoxical effects of Jewish community size on Jewish communal behavior: Intermarriage, synagogue membership and giving to local Jewish Federations. Contemporary Jewry, 1989, 10, 9-15.	0.5	3
180	Why Ongoing Supervision in Social Casework:. Clinical Supervisor, The, 1987, 5, 79-90.	1.7	12

#	Article	IF	CITATIONS
181	Board of Directors: A Case Study in Group Process and Object Relations. Group Analysis, 1986, 19, 347-354.	0.2	O
182	Discussion on Paper by Jonathan Rabinowitz. Group Analysis, 1986, 19, 354-355.	0.2	0
183	The haircut: Its meaning in childhood. Tradition, 1984, 1, 270-279.	0.2	2
184	?Red rover?: An expression of the psychic struggle toward separation-individuation. American Journal of Psychoanalysis, 1984, 44, 425-430.	0.4	0